Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 influences lung microbiota dynamics and favors the emergence of rare infectious diseases: A case report of *Hafnia Alvei* pneumonia.

Salvatore Lucio Cutulia a,⁎, Flavio De Maio b,1, Gennaro De Pascale a,1, Domenico Luca Grieco a, Francesca Romana Monzo b, Simone Carelli a, Eloisa Sofia Tanzarella a, Gabriele Pintaudi a, Edoardo Piervincenzi a, Laura Cascarano a, Rikardo Xhemalaj a, Maurizio Sanguinetti b,⁎, Brunella Posteraro c,d, Teresa Spanu b,c,2, Massimo Antonelli a,c,2

a Dipartimento di Scienze dell’Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

b Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

c Facoltà di medicina e chirurgia “A. Gemelli”, Università Cattolica del Sacro Cuore, Rome, Italy

d Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

**Abstract**

**Keywords:**
ARDS
Critical care
Pneumonia
Sepsis
COVID-19
Hafnia Alvei

The coronavirus disease 2019 (COVID-19) pandemic has been challenging patients, clinicians and healthcare systems worldwide [1]. Although mechanical ventilation (MV) represents a cornerstone of therapy for patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 [2], such an intervention has been identified as a risk factor for ventilator-associated pneumonia (VAP) [3]. Specifically, COVID-19 may cause immune system dysfunction [4] and respiratory tract dysbiosis [5], both fostering the development of secondary infections [6].

In the light of this view, we sought to report lung microbiota dynamics in a critically ill patient with COVID-19, who required MV and developed *Hafnia alvei* ventilator-associated pneumonia and required extracorporeal membrane oxygenation support.

1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic has been challenging patients, clinicians and healthcare systems worldwide [1]. Although mechanical ventilation (MV) represents a cornerstone of therapy for patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 [2], such an intervention has been identified as a risk factor for ventilator-associated pneumonia (VAP) [3]. Specifically, COVID-19 may cause immune system dysfunction [4] and respiratory tract dysbiosis [5], both fostering the development of secondary infections [6].

In the light of this view, we sought to report lung microbiota dynamics in a critically ill patient with COVID-19, who required MV and developed *Hafnia alvei* VAP [7].

2. Material and methods

The study was approved by the human research ethics committee of the Fondazione Policlinico A. Gemelli IRCCS (reference number: 1847). The patient provided specific signed permission for the publication.

COVID-19 was diagnosed by reverse transcription-polymerase chain reaction, which was performed on nasopharyngeal swab at hospital admission. Bacterial identification on bronchoalveolar lavage (BAL) culture was performed by MALDI BioTyper® system (Bruker Daltonics, Bremen, Germany) and microbiota analysis was performed by sequencing of amplified 16S rRNA gene V3–V4 and V6 regions. Bacterial richness was assessed by Shannon’s diversity index and bacterial equitability was evaluated by Pielou’s evenness index.

3. Results

We reported the case of a 52-years-old male who was admitted to the ICU of a tertiary university hospital in Italy for ARDS caused by COVID-19 (eTable1). Although he received Dexamethasone and Remdesivir, invasive MV was necessary to improve life-threatening hypoxemia (eTable1). BAL was performed immediately after endotracheal intubation (T1, Fig. 1) and revealed no bacterial growth.
Accordingly, empiric antibiotic therapy with Piperacillin-Tazobactam was stopped.

Patient's clinical condition progressively worsened (eTable2) and veno-venous extracorporeal membrane oxygenation was commenced as a rescue organ support for severe ARDS (eFigure 1A). A second BAL (T2, Fig. 1) was performed and allowed the diagnosis of *Hafnia alvei* VAP (eTable3). Accordingly, empiric antibiotic therapy with intravenous Meropenem was deemed appropriate and continued until clinical improvement and microbiological eradication. Patient's clinical condition progressively improved (eFigure 1B) and he was discharged alive after 114 days of hospital stay (Supplementary eTable4).

The analyses of T1 and T2 (Fig. 1) provided important insight into microbiota dynamics and revealed significant dysbiosis associated with COVID-19 and *Hafnia alvei* VAP. Bacterial richness and equitability decreased from T1 to T2 (Shannon's diversity index: 3.898 for T1 and 0.522 for T2; Pielou's evenness index: 0.737 for T1 and 0.111 for T2), which corresponded to a transition from *Firmicutes* (54.2%) and *Bacteroidetes* (35.0%) predominance in T1 to *Proteobacteria* (91.1%) in T2.

### 4. Discussion

We reported clinical characteristics of a critically ill patient admitted to the ICU with ARDS caused by COVID-19, who developed *Hafnia alvei* VAP. Moreover, we described lung microbiota dysbiosis associated with COVID-19 and *Hafnia alvei* secondary infection.

*Hafnia alvei* is a gram-negative bacterium that belongs to *Enterobacteriaceae* and has been rarely reported as a pathogen that causes respiratory tract infections, especially in immunocompromised patients [7]. Recently, Blonz et al [3] observed a significant incidence of VAP caused by *Hafnia alvei* (3.9% of respiratory isolates) in critically ill patients with COVID-19. In this study [3], *Enterobacteriaceae* were isolated in 49.8% of respiratory samples, which may support the pathophysiological hypothesis of COVID-19 induced gut dysbiosis [8] and gut-lung crosstalk. Moreover, male sex represented a risk factor for the development of VAP, that may imply the influence of genetic and hormonal status on immune response. As a result, the emergence of rare infectious diseases in critically ill patients with COVID-19 may be favored by concurrent genetic [3], viral [4] and steroid [9] induced immune dysfunction, in a context of viral [8] and antibiotic induced multi-organ dysbiosis [10].

Our findings implicate that immune dysfunction fosters the development of rare and life-threatening bacterial infections. In this context, microbiota analysis represents a potential monitoring tool of dysbiosis, which may play a role in the prediction and early diagnosis of infectious diseases [10]. Moreover, such analysis may provide important information on the effect of multiple interventions (e.g. pharmacological therapies, MV setting and nutrition) on microbiota balance, in order to orient clinical decision-making towards strategies that allow native microbiota preservation.

This is the first report of *Hafnia alvei* infection and lung microbiota dysbiosis in a patient with COVID-19. Although our experience is restricted to one patient, *Hafnia alvei* infections and lung dysbiosis are...
rarely described in the literature and even a single, detailed, case scenario may be of interest when characterized by these important clinical implications.

5. Conclusion

*Hafnia alvei* was rarely associated with pneumonia in critically ill patients before COVID-19 pandemic. Immune dysfunction and dysbiosis caused by both COVID-19 and clinical interventions may justify the emergence of rare pathogenic threats. In this context, microbiota analysis represents a potential monitoring tool in order to prevent and early diagnose infectious diseases.

**Funding**

This work was partially supported by grants from the Italian Ministry for University and Scientific Research, Italy (GR-2018-12367375).

**Author contributions**

Conceptualization: SLC, GDP, TS, MA; Data curation: SLC, DLG, SC, EST, GP, EP, LC and RX; Formal analysis: SLC, FDM, FRM; Funding acquisition: GDP, MA, BP, TS, MA; Investigation: SLC, FDM, GDP, DLG, FRM, SC, EST, GP, EP, LC and RX, MS, BP, TS, MA; Methodology: SLC, FDM, GDP, MS, BP, TS, MA; Project administration: SLC, FDM, GDP, MS, BP, TS, MA; Resources: SLC, GDP, MS, BP, TS, MA; Software: STATA and R; Supervision: SLC, FDM, GDP, MS, BP, TS, MA; Validation: SLC, FDM, GDP, MS, BP, TS, MA; Visualization: SLC, FDM, GDP, MS, BP, TS, MA; Writing - original draft: SLC, FDM, GDP, MS, BP, TS, MA; Writing - review & editing: SLC, FDM, GDP, MS, BP, TS, MA.

**Declaration of Competing Interest**

None.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jcrc.2021.04.008.

**References**

[1] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region. Italy JAMA. 2020;323(16):1574–81. https://doi.org/10.1001/jama.2020.5394.

[2] Kassirian S, Taneja R, Mehta S. Diagnosis and Management of Acute Respiratory Distress Syndrome in a time of COVID-19. Diagnostics (Basel). 2020;10(12):1053. https://doi.org/10.3390/diagnostics10121053.

[3] Bloné G, Kouatch et A. Chudeau N, Pontis E, Lober J, Lemeur A, et al. Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an un-inundated French region. Crit Care. 2021;25(1):72. https://doi.org/10.1186/s13054-021-03493-w.

[4] Jeanret R, Daix T, Formento R, Feuillard J, François B. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression. Intensive Care Med. 2020;46(9):1769–71. https://doi.org/10.1007/s00134-020-06127-x.

[5] Bao L, Zhang C, Dong J, Zhao L, Li Y, Sun J. Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection. Front Microbiol. 2020;11:1840. https://doi.org/10.3389/fmicb.2020.01840.

[6] Rouzé A, Martin-Loeches L, Povo P, Makris D, Artigas A, Boucheveau M, et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021;1–11. https://doi.org/10.1007/s00134-020-06323-9 Online ahead of print.

[7] Bao L, Zhang C, Dong J, Zhao L, Li Y, Sun J. Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection. Front Microbiol. 2020;11:1840. https://doi.org/10.3389/fmicb.2020.01840.

[8] De Rosa S, Cutuli SL, Ferver R, Antonelli M, Ronco C. COVID-19 EUPHAS2 Collaborative Group. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry. Artif Organs. 2020. https://doi.org/10.1111/aor.13900 Online ahead of print.

[9] Lazzarino M, Orlandi E, Baldanti F, Fusione M, Pagnucco G, Astori C, et al. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Br J Haematol. 1999;107(4):877–82. https://doi.org/10.1046/j.1365-2141.1999.01765.x.

[10] Fromentin M, Ricard J, Roux D. Respiratory microbiome in mechanically ventilated patients: a narrative review. Intensive Care Med. 2012;1–15. https://doi.org/10.1007/s00134-020-06338-2 Online ahead of print.